Which type of leukemia does Giritinib (Segatan) mainly treat and its indications?

Gilteritinib (Gilteritinib) is an oral FLT3 inhibitor, mainly targeting patients with acute myeloid leukemia (AML) with FLT3 gene mutations. FLT3mutation is one of the most common genetic abnormalities in AML, accounting for about 20%–30% of patients, and is usually associated with rapid disease progression, high relapse rate, and poor prognosis. Giritinib inhibits the growth and spread of leukemia cells by selectively inhibiting the activity of FLT3 receptor tyrosine kinase and blocking tumor cell proliferation signals.

In terms of indications, gilitinib is mainly approved for the treatment of patients with relapsed or refractory FLT3 mutated AML. Such patients often still experience disease recurrence after receiving conventional chemotherapy or hematopoietic stem cell transplantation, and have limited treatment options and poor prognosis. The emergence of giritinib provides a new targeted therapy for these patients, which not only improves the complete response rate, but also significantly extends the progression-free survival and overall survival.

Clinical studies have shown that giritinib has a high efficacy in the single-agent treatment of relapsed/refractory AML. For example, in the ADMIRAL study, the median overall survival of the geritinib group was significantly better than that of the traditional chemotherapy group (9.3 months vs 5.6 months), and was relatively well tolerated. This result makes giritinib an important option for the current treatment of patients with FLT3 mutated AML relapsed or refractory, and has gradually been included in international treatment guidelines.

In addition, giritinib is also exploring its combination with other drugs, such as standard chemotherapy or low-dose hypomethylating drugs, in order to further improve the efficacy of treatment-naïve and high-risk AML patients. Although these combination therapies are still in clinical trials, they show some promise. In general, the main treatment targets of giritinib are patients with relapsed or refractory AML with FLT3 mutations. Its targeted therapy has significant advantages and provides new hope for survival for this type of high-risk leukemia population.

Reference materials:https://www.drugs.com/